Imaging of lymphoma:
Gespeichert in:
| Format: | Buch |
|---|---|
| Sprache: | English |
| Veröffentlicht: |
Philadelphia [u.a.]
Saunders
2008
|
| Schriftenreihe: | Radiologic clinics of North America
46,2 |
| Schlagworte: | |
| Online-Zugang: | Inhaltsverzeichnis |
| Beschreibung: | XIII S., S. 175 - 437 zahlr. Ill., graph. Darst. |
| ISBN: | 1416063471 9781416063476 |
Internformat
MARC
| LEADER | 00000nam a2200000 cb4500 | ||
|---|---|---|---|
| 001 | BV035043866 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | t | ||
| 008 | 080909s2008 ad|| |||| 00||| eng d | ||
| 020 | |a 1416063471 |9 1-4160-6347-1 | ||
| 020 | |a 9781416063476 |9 978-1-4160-6347-6 | ||
| 035 | |a (OCoLC)234193369 | ||
| 035 | |a (DE-599)HBZHT015659599 | ||
| 040 | |a DE-604 |b ger |e rakwb | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-19 |a DE-91 | ||
| 050 | 0 | |a RM846 | |
| 082 | 0 | |a 616.42/07572 |2 22 | |
| 245 | 1 | 0 | |a Imaging of lymphoma |c guest ed. Jürgen Rademaker |
| 264 | 1 | |a Philadelphia [u.a.] |b Saunders |c 2008 | |
| 300 | |a XIII S., S. 175 - 437 |b zahlr. Ill., graph. Darst. | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 490 | 1 | |a Radiologic clinics of North America |v 46,2 | |
| 650 | 4 | |a Diagnostic Imaging | |
| 650 | 4 | |a Fluorodeoxyglucose F18 |x therapeutic use | |
| 650 | 4 | |a Hodgkin Disease |x diagnosis | |
| 650 | 4 | |a Lymphoma, Non-Hodgkin |x diagnosis | |
| 650 | 4 | |a Lymphomas |x Imaging | |
| 650 | 4 | |a Positron Emission Tomography | |
| 700 | 1 | |a Rademaker, Jürgen |e Sonstige |4 oth | |
| 830 | 0 | |a Radiologic clinics of North America |v 46,2 |w (DE-604)BV000003369 |9 46,2 | |
| 856 | 4 | 2 | |m HBZ Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=016712650&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-016712650 | ||
Datensatz im Suchindex
| _version_ | 1804137979969536000 |
|---|---|
| adam_text | Contents
Preface xiii
Jiirgen Rademaker
Overview of Lymphoma Diagnosis and Management 175
Matthew J. Matasarand Andrew D.Zelenetz
The malignant lymphomas, including both Hodgkin lymphoma (HL) and non-Hodg-
kin lymphoma (NHL), represent a diverse group of diseases that arise from a clonal
proliferation of lymphocytes. Each of the more than 30 unique types of lymphoma is
a disease with a distinct natural history. This biologic heterogeneity gives rise to
marked differences among the lymphomas with respect to epidemiology, pathologic
characteristics, clinical presentation, and optimal management. This article empha¬
sizes the principles of diagnosis, including appropriate pathologic evaluation and
staging considerations, and focuses on the clinical presentation, staging, and opti¬
mal management strategies for the most common types of lymphoma.
The Impact of Fluorodeoxyglucose-Positron EmissionTomography in Primary
Staging and Patient Management in Lymphoma Patients 199
Martin Allen-Auerbach, Sven deVos, andJohannes Czernin
Fully diagnostic positron emission tomography (PET)/CT scans acquired during oral
and intravenous contrast can be provided to patients and referring physicians in
a single imaging session. Although FDG uptake varies, most low-grade lymphomas
exhibit sufficient FDG avidity to also be staged reliably with FDG PET/CT. PET/CT
imaging is more accurate for lymphoma staging than PET or CT alone and has sub¬
stantial impact on patient management. This accurate whole-body glucose meta¬
bolic survey should serve as the baseline for subsequent treatment response
evaluations. PET/CT has evolved to become the modality of choice for staging of
nodal and extranodal lymphoma, for assessing therapeutic response, and for estab¬
lishing patient prognosis.
New Staging and Response Criteria for Non-Hodgkin Lymphoma
and Hodgkin Lymphoma 213
Bruce D. Cheson
The International Harmonization Project developed recommendations for the use of
positron emission tomography (PET) in managing patients who have lymphoma. It
provided guidance as to the interpretation of fluorodeoxyglucose (FDG) PET and
generated response definitions, incorporating metabolic imaging with the goal of im¬
proving interpretation of response and comparability among studies, leading to ac¬
celerated new agent development, more rapid availability of more effective
therapies, and the enhancement of outcome for patients with lymphoma.
Contents
PET Imaging for Response Assessment in Lymphoma: Potential and Limitations 225
HeikoSchoder and Craig Moskowitz
Fluorodeoxyglucose positron emission tomography (FDG-PET) is now considered
the most accurate tool for the assessment of treatment response and prognosis in
patients with Hodgkin lymphoma and aggressive non-Hodgkin lymphoma. This ar¬
ticle discusses the potential and limitations of FDG-PET for response assessment
in malignant lymphoma during chemotherapy (interim PET) and at the end of chemo¬
therapy. Interim PET is used to predict the likelihood for a complete response at the
end of such therapy. End-of-treatment PET aims to establish the completeness of
response or the presence of residual viable tumor tissue. Until the results of ongoing
clinical trials emerge over the next 5 years, interim PET should be considered inves-
tigational and should not be used for patient management outside of study
protocols.
Perspectives of Molecular Imaging and Radioimmunotherapy in Lymphoma 243
Andrei lagaru, Michael L. Goris, and Sanjiv Sam Gambhir
Successful treatment of Hodgkin lymphomas and non-Hodgkin lymphomas de¬
pends on accurate staging and prognostic estimations, as well as evaluation of re¬
sponse to therapy as early after initiation as possible. We focus on several aspects of
molecular imaging and therapy that affect the management of patients who have
lymphoma. First, we review prior use of gallium-67 citrate for evaluation of lym¬
phoma patients, mainly from a historical perspective, since it was the mainstream
lymphoma functional imaging tracer for decades. Next, we review current clinical
uses of 18F Fluoro-2-Deoxyglucose (18F FDG) PET and PET/CT for evaluation of
lymphoma patients and use of radioimmunotherapy in lymphoma. Finally, we dis¬
cuss advances in molecular imaging that may herald the next generation of PET ra-
diotracers after 18F FDG.
Cross-Sectional Evaluation of Thoracic Lymphoma 253
Young A Bae and Kyung Soo Lee
In patients who have lymphoma, the presence and distribution of thoracic involve¬
ment is important in both tumor staging and treatment. Thoracic involvement in
Hodgkin lymphoma (HL) is more common than in non-Hodgkin lymphoma (NHL).
In HL, mediastinal lymphadenopathy with contiguous spread is a hallmark, and
lung parenchymal involvement at the initial presentation is almost always associated
with mediastinal lymphadenopathy. NHL is more heterogeneous and generally pres¬
ents at a more advanced stage than HL. Most often, mediastinal involvement occurs
as a disseminated or recurrent form of extrathoracic lymphoma. Bulky mediastinal
disease with compression of adjacent structures can occur, particularly with high-
grade subtypes of NHL and isolated lung disease without mediastinal lymphadenop¬
athy can occur in contrast to HL.
Imaging of Abdominal Lymphoma 265
Munazza Anis and Abid Irshad
This article discusses the radiologic appearances of solid organ involvement with
Hodgkin and non-Hodgkin lymphoma in the abdominopelvic region. The most com¬
mon radiologic patterns of involvement are illustrated. The imaging characteristics of
lymphomatous involvement of abdominal organs overlap with several other disor¬
ders and the specific features pertaining to lymphoma are highlighted. In patients
Contents
who have known lymphomas, other important management considerations, such as
staging, response to therapy, malignant transformation, and identification of recur¬
rent disease, are also discussed. The emerging role of fluorodeoxyglucose positron
emission tomography is briefly outlined.
Imaging of Gastrointestinal Lymphoma 287
Marc J. Gollub
The gastrointestinal (Gl) tract contains the largest collection of lymphocytes any¬
where in the body. Gl lymphoma may arise at any site in the Gl tract but typically in¬
volves the stomach and small bowel in cases of systemic disease. Most cases are
non-Hodgkin B-cell type. Enteropathy-associated T cell lymphoma can complicate
celiac disease. Less commonly, lymphoma may originate in the Gl tract without sys¬
temic involvement. This sometimes occurs in response to chronic infections. This ar¬
ticle discusses the role of imaging in detecting and staging Gl tract lymphomas,
using fluoroscopy and cross-sectional imaging, primarily CT.
Imaging of Pediatric Lymphomas 313
SaraJ. Abramson and Anita P. Price
Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) represent 10% to 15%
of all malignancies occurring in children younger than 20 years of age. Advances in
cross-sectional imaging and the availability of positron emission tomography (PET)
and PET-CT have had a major impact on imaging and management of pediatric pa¬
tients. This article reviews the clinical features of lymphoma, focusing on the spec¬
trum of imaging findings seen in diagnosis, staging, and follow-up of HL and NHL.
Pediatric NHL has four major histologic subtypes: Burkitt lymphoma, diffuse large
B-cell lymphoma, anaplastic large cell lymphoma, and lymphoblastic lymphoma.
The most important subtype of HL is nodular sclerosis.
Imaging of Lymphoma of the Central Nervous System, Spine, and Orbit 339
Sofia Haque, Meng Law, Lauren E. Abrey, and Robert J.Young
Lymphomas of the central nervous system, spine, and orbit consist of both systemic
lymphomas and primary central nervous system lymphomas. This article addresses
the typical imaging findings of lymphoma in both immunocompetent and immuno-
compromised patients, discusses the differential possibilities, and reviews the re¬
sponse criteria being used in clinical trials. Also described are metabolic imaging
techniques with nuclear medicine and advanced MR imaging and how they can
help improve the understanding of tumor biology.
Imaging Hodgkin and Non-Hodgkin Lymphoma in the Head and Neck 363
Ashley H. Aiken and Christine Glastonbury
Hodgkin (HL) and non-Hodgkin lymphoma (NHL) involving the head and neck have
many overlapping imaging features. Definitive diagnosis depends on histology, but
imaging trends may help distinguish lymphoma from other common pathologic en¬
tities in the head and neck. CT is useful for staging and assessing bony involvement,
whereas MR imaging is performed for soft tissue detail in extranodal disease, espe¬
cially when there is transpatial disease or intracranial or intraspinal extension. Pos¬
itron emission tomography has become an important part of 6taging and
Contents
surveillance imaging and is particularly useful to distinguish posttreatment fibrosis
and residual tumor.
Imaging of Lymphoma of the Musculoskeletal System 379
Sinchun Hwang
Imaging plays a crucial role in staging and the assessment of treatment response in
patients who have lymphoma of the musculoskeletal system. This article reviews im¬
aging features of lymphoma of bone, muscles, cutaneous, and subcutaneous tissue.
At radiography, lymphoma of the bone is most commonly lytic, but the affected bone
also can appear deceivingly normal, even when a large tumor is present. At CT, lym¬
phoma of muscle can be homogenous in attenuation, and it may not show contrast
enhancement, making tumor detection more difficult. Post-treatment changes often
are encountered at MR imaging and positron emission tomography, and when con¬
sidered in light of the patient s therapy regimen (eg, radiation therapy and granulo-
cyte-colony stimulating factor), they usually can be differentiated from tumor. Post-
treatment changes include diffuse FDG uptake in marrow after chemotherapy, indi¬
cating rebound of normal marrow, and MR imaging signal abnormalities that may
persist for anywhere from a few months to years after treatment.
Imaging of Complications of Hematopoietic Stem Cell Transplantation 397
Jyothi P. Jagannathan, Nikhil Ramaiya, Ritu R. Gill, Edwin Pascal Alyea III, and Pablo Ros
Hematopoietic stem cell transplantation is increasingly used for treatment of malig¬
nant and nonmalignant disorders, genetic and immunologic disorders, and solid tu¬
mors. Although advances in immunosuppressive therapy and management of
infections have improved long-term survival, transplant recipients remain at risk
for a multitude of complications, many of which are serious and life threatening.
Posttransplant complications may be classified either according to the organ system
or according to the timeframe following transplantation. Complications may involve
the chest, abdominopelvic organs, the central nervous system, or musculoskeletal
tissues. This article reviews the various clinical and radiologic findings of key com¬
plications following hematopoietic stem cell transplantation and the pertinent differ¬
entiating factors.
Imaging of Late Complications from Mantle Field Radiation in Lymphoma Patients 419
Sandra Brennan, Lucy E. Hann, Joachim Yahalom, Kevin C. Oeff inger, and Jiirgen Rademaker
Hodgkin lymphoma is one of the most curable cancers because of its sensitivity to
both radiation and several chemotherapy agents. Radical radiotherapy alone pro¬
vided curative therapy for patients who had Hodgkin lymphoma as early as six de¬
cades ago. Yet, the radiation field included normal organs, such as breast tissue,
thyroid, and coronary arteries, which were at risk for long-term complications. Ded¬
icated imaging approaches have been developed to evaluate late radiation effects
on these structures.
Index 431
Erratum 437
|
| adam_txt |
Contents
Preface xiii
Jiirgen Rademaker
Overview of Lymphoma Diagnosis and Management 175
Matthew J. Matasarand Andrew D.Zelenetz
The malignant lymphomas, including both Hodgkin lymphoma (HL) and non-Hodg-
kin lymphoma (NHL), represent a diverse group of diseases that arise from a clonal
proliferation of lymphocytes. Each of the more than 30 unique types of lymphoma is
a disease with a distinct natural history. This biologic heterogeneity gives rise to
marked differences among the lymphomas with respect to epidemiology, pathologic
characteristics, clinical presentation, and optimal management. This article empha¬
sizes the principles of diagnosis, including appropriate pathologic evaluation and
staging considerations, and focuses on the clinical presentation, staging, and opti¬
mal management strategies for the most common types of lymphoma.
The Impact of Fluorodeoxyglucose-Positron EmissionTomography in Primary
Staging and Patient Management in Lymphoma Patients 199
Martin Allen-Auerbach, Sven deVos, andJohannes Czernin
Fully diagnostic positron emission tomography (PET)/CT scans acquired during oral
and intravenous contrast can be provided to patients and referring physicians in
a single imaging session. Although FDG uptake varies, most low-grade lymphomas
exhibit sufficient FDG avidity to also be staged reliably with FDG PET/CT. PET/CT
imaging is more accurate for lymphoma staging than PET or CT alone and has sub¬
stantial impact on patient management. This accurate whole-body glucose meta¬
bolic survey should serve as the baseline for subsequent treatment response
evaluations. PET/CT has evolved to become the modality of choice for staging of
nodal and extranodal lymphoma, for assessing therapeutic response, and for estab¬
lishing patient prognosis.
New Staging and Response Criteria for Non-Hodgkin Lymphoma
and Hodgkin Lymphoma 213
Bruce D. Cheson
The International Harmonization Project developed recommendations for the use of
positron emission tomography (PET) in managing patients who have lymphoma. It
provided guidance as to the interpretation of fluorodeoxyglucose (FDG) PET and
generated response definitions, incorporating metabolic imaging with the goal of im¬
proving interpretation of response and comparability among studies, leading to ac¬
celerated new agent development, more rapid availability of more effective
therapies, and the enhancement of outcome for patients with lymphoma.
Contents
PET Imaging for Response Assessment in Lymphoma: Potential and Limitations 225
HeikoSchoder and Craig Moskowitz
Fluorodeoxyglucose positron emission tomography (FDG-PET) is now considered
the most accurate tool for the assessment of treatment response and prognosis in
patients with Hodgkin lymphoma and aggressive non-Hodgkin lymphoma. This ar¬
ticle discusses the potential and limitations of FDG-PET for response assessment
in malignant lymphoma during chemotherapy (interim PET) and at the end of chemo¬
therapy. Interim PET is used to predict the likelihood for a complete response at the
end of such therapy. End-of-treatment PET aims to establish the completeness of
response or the presence of residual viable tumor tissue. Until the results of ongoing
clinical trials emerge over the next 5 years, interim PET should be considered inves-
tigational and should not be used for patient management outside of study
protocols.
Perspectives of Molecular Imaging and Radioimmunotherapy in Lymphoma 243
Andrei lagaru, Michael L. Goris, and Sanjiv Sam Gambhir
Successful treatment of Hodgkin lymphomas and non-Hodgkin lymphomas de¬
pends on accurate staging and prognostic estimations, as well as evaluation of re¬
sponse to therapy as early after initiation as possible. We focus on several aspects of
molecular imaging and therapy that affect the management of patients who have
lymphoma. First, we review prior use of gallium-67 citrate for evaluation of lym¬
phoma patients, mainly from a historical perspective, since it was the mainstream
lymphoma functional imaging tracer for decades. Next, we review current clinical
uses of 18F Fluoro-2-Deoxyglucose (18F FDG) PET and PET/CT for evaluation of
lymphoma patients and use of radioimmunotherapy in lymphoma. Finally, we dis¬
cuss advances in molecular imaging that may herald the next generation of PET ra-
diotracers after 18F FDG.
Cross-Sectional Evaluation of Thoracic Lymphoma 253
Young A Bae and Kyung Soo Lee
In patients who have lymphoma, the presence and distribution of thoracic involve¬
ment is important in both tumor staging and treatment. Thoracic involvement in
Hodgkin lymphoma (HL) is more common than in non-Hodgkin lymphoma (NHL).
In HL, mediastinal lymphadenopathy with contiguous spread is a hallmark, and
lung parenchymal involvement at the initial presentation is almost always associated
with mediastinal lymphadenopathy. NHL is more heterogeneous and generally pres¬
ents at a more advanced stage than HL. Most often, mediastinal involvement occurs
as a disseminated or recurrent form of extrathoracic lymphoma. Bulky mediastinal
disease with compression of adjacent structures can occur, particularly with high-
grade subtypes of NHL and isolated lung disease without mediastinal lymphadenop¬
athy can occur in contrast to HL.
Imaging of Abdominal Lymphoma 265
Munazza Anis and Abid Irshad
This article discusses the radiologic appearances of solid organ involvement with
Hodgkin and non-Hodgkin lymphoma in the abdominopelvic region. The most com¬
mon radiologic patterns of involvement are illustrated. The imaging characteristics of
lymphomatous involvement of abdominal organs overlap with several other disor¬
ders and the specific features pertaining to lymphoma are highlighted. In patients
Contents
who have known lymphomas, other important management considerations, such as
staging, response to therapy, malignant transformation, and identification of recur¬
rent disease, are also discussed. The emerging role of fluorodeoxyglucose positron
emission tomography is briefly outlined.
Imaging of Gastrointestinal Lymphoma 287
Marc J. Gollub
The gastrointestinal (Gl) tract contains the largest collection of lymphocytes any¬
where in the body. Gl lymphoma may arise at any site in the Gl tract but typically in¬
volves the stomach and small bowel in cases of systemic disease. Most cases are
non-Hodgkin B-cell type. Enteropathy-associated T cell lymphoma can complicate
celiac disease. Less commonly, lymphoma may originate in the Gl tract without sys¬
temic involvement. This sometimes occurs in response to chronic infections. This ar¬
ticle discusses the role of imaging in detecting and staging Gl tract lymphomas,
using fluoroscopy and cross-sectional imaging, primarily CT.
Imaging of Pediatric Lymphomas 313
SaraJ. Abramson and Anita P. Price
Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) represent 10% to 15%
of all malignancies occurring in children younger than 20 years of age. Advances in
cross-sectional imaging and the availability of positron emission tomography (PET)
and PET-CT have had a major impact on imaging and management of pediatric pa¬
tients. This article reviews the clinical features of lymphoma, focusing on the spec¬
trum of imaging findings seen in diagnosis, staging, and follow-up of HL and NHL.
Pediatric NHL has four major histologic subtypes: Burkitt lymphoma, diffuse large
B-cell lymphoma, anaplastic large cell lymphoma, and lymphoblastic lymphoma.
The most important subtype of HL is nodular sclerosis.
Imaging of Lymphoma of the Central Nervous System, Spine, and Orbit 339
Sofia Haque, Meng Law, Lauren E. Abrey, and Robert J.Young
Lymphomas of the central nervous system, spine, and orbit consist of both systemic
lymphomas and primary central nervous system lymphomas. This article addresses
the typical imaging findings of lymphoma in both immunocompetent and immuno-
compromised patients, discusses the differential possibilities, and reviews the re¬
sponse criteria being used in clinical trials. Also described are metabolic imaging
techniques with nuclear medicine and advanced MR imaging and how they can
help improve the understanding of tumor biology.
Imaging Hodgkin and Non-Hodgkin Lymphoma in the Head and Neck 363
Ashley H. Aiken and Christine Glastonbury
Hodgkin (HL) and non-Hodgkin lymphoma (NHL) involving the head and neck have
many overlapping imaging features. Definitive diagnosis depends on histology, but
imaging trends may help distinguish lymphoma from other common pathologic en¬
tities in the head and neck. CT is useful for staging and assessing bony involvement,
whereas MR imaging is performed for soft tissue detail in extranodal disease, espe¬
cially when there is transpatial disease or intracranial or intraspinal extension. Pos¬
itron emission tomography has become an important part of 6taging and
Contents
surveillance imaging and is particularly useful to distinguish posttreatment fibrosis
and residual tumor.
Imaging of Lymphoma of the Musculoskeletal System 379
Sinchun Hwang
Imaging plays a crucial role in staging and the assessment of treatment response in
patients who have lymphoma of the musculoskeletal system. This article reviews im¬
aging features of lymphoma of bone, muscles, cutaneous, and subcutaneous tissue.
At radiography, lymphoma of the bone is most commonly lytic, but the affected bone
also can appear deceivingly normal, even when a large tumor is present. At CT, lym¬
phoma of muscle can be homogenous in attenuation, and it may not show contrast
enhancement, making tumor detection more difficult. Post-treatment changes often
are encountered at MR imaging and positron emission tomography, and when con¬
sidered in light of the patient's therapy regimen (eg, radiation therapy and granulo-
cyte-colony stimulating factor), they usually can be differentiated from tumor. Post-
treatment changes include diffuse FDG uptake in marrow after chemotherapy, indi¬
cating rebound of normal marrow, and MR imaging signal abnormalities that may
persist for anywhere from a few months to years after treatment.
Imaging of Complications of Hematopoietic Stem Cell Transplantation 397
Jyothi P. Jagannathan, Nikhil Ramaiya, Ritu R. Gill, Edwin Pascal Alyea III, and Pablo Ros
Hematopoietic stem cell transplantation is increasingly used for treatment of malig¬
nant and nonmalignant disorders, genetic and immunologic disorders, and solid tu¬
mors. Although advances in immunosuppressive therapy and management of
infections have improved long-term survival, transplant recipients remain at risk
for a multitude of complications, many of which are serious and life threatening.
Posttransplant complications may be classified either according to the organ system
or according to the timeframe following transplantation. Complications may involve
the chest, abdominopelvic organs, the central nervous system, or musculoskeletal
tissues. This article reviews the various clinical and radiologic findings of key com¬
plications following hematopoietic stem cell transplantation and the pertinent differ¬
entiating factors.
Imaging of Late Complications from Mantle Field Radiation in Lymphoma Patients 419
Sandra Brennan, Lucy E. Hann, Joachim Yahalom, Kevin C. Oeff inger, and Jiirgen Rademaker
Hodgkin lymphoma is one of the most curable cancers because of its sensitivity to
both radiation and several chemotherapy agents. Radical radiotherapy alone pro¬
vided curative therapy for patients who had Hodgkin lymphoma as early as six de¬
cades ago. Yet, the radiation field included normal organs, such as breast tissue,
thyroid, and coronary arteries, which were at risk for long-term complications. Ded¬
icated imaging approaches have been developed to evaluate late radiation effects
on these structures.
Index 431
Erratum 437 |
| any_adam_object | 1 |
| any_adam_object_boolean | 1 |
| building | Verbundindex |
| bvnumber | BV035043866 |
| callnumber-first | R - Medicine |
| callnumber-label | RM846 |
| callnumber-raw | RM846 |
| callnumber-search | RM846 |
| callnumber-sort | RM 3846 |
| callnumber-subject | RM - Therapeutics and Pharmacology |
| ctrlnum | (OCoLC)234193369 (DE-599)HBZHT015659599 |
| dewey-full | 616.42/07572 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 616 - Diseases |
| dewey-raw | 616.42/07572 |
| dewey-search | 616.42/07572 |
| dewey-sort | 3616.42 47572 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| discipline_str_mv | Medizin |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01495nam a2200397 cb4500</leader><controlfield tag="001">BV035043866</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">080909s2008 ad|| |||| 00||| eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">1416063471</subfield><subfield code="9">1-4160-6347-1</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781416063476</subfield><subfield code="9">978-1-4160-6347-6</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)234193369</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)HBZHT015659599</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-19</subfield><subfield code="a">DE-91</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RM846</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">616.42/07572</subfield><subfield code="2">22</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Imaging of lymphoma</subfield><subfield code="c">guest ed. Jürgen Rademaker</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Philadelphia [u.a.]</subfield><subfield code="b">Saunders</subfield><subfield code="c">2008</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">XIII S., S. 175 - 437</subfield><subfield code="b">zahlr. Ill., graph. Darst.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">Radiologic clinics of North America</subfield><subfield code="v">46,2</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Diagnostic Imaging</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Fluorodeoxyglucose F18</subfield><subfield code="x">therapeutic use</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Hodgkin Disease</subfield><subfield code="x">diagnosis</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Lymphoma, Non-Hodgkin</subfield><subfield code="x">diagnosis</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Lymphomas</subfield><subfield code="x">Imaging</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Positron Emission Tomography</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Rademaker, Jürgen</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="830" ind1=" " ind2="0"><subfield code="a">Radiologic clinics of North America</subfield><subfield code="v">46,2</subfield><subfield code="w">(DE-604)BV000003369</subfield><subfield code="9">46,2</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">HBZ Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=016712650&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-016712650</subfield></datafield></record></collection> |
| id | DE-604.BV035043866 |
| illustrated | Illustrated |
| index_date | 2024-07-02T21:54:07Z |
| indexdate | 2024-07-09T21:20:54Z |
| institution | BVB |
| isbn | 1416063471 9781416063476 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-016712650 |
| oclc_num | 234193369 |
| open_access_boolean | |
| owner | DE-19 DE-BY-UBM DE-91 DE-BY-TUM |
| owner_facet | DE-19 DE-BY-UBM DE-91 DE-BY-TUM |
| physical | XIII S., S. 175 - 437 zahlr. Ill., graph. Darst. |
| publishDate | 2008 |
| publishDateSearch | 2008 |
| publishDateSort | 2008 |
| publisher | Saunders |
| record_format | marc |
| series | Radiologic clinics of North America |
| series2 | Radiologic clinics of North America |
| spelling | Imaging of lymphoma guest ed. Jürgen Rademaker Philadelphia [u.a.] Saunders 2008 XIII S., S. 175 - 437 zahlr. Ill., graph. Darst. txt rdacontent n rdamedia nc rdacarrier Radiologic clinics of North America 46,2 Diagnostic Imaging Fluorodeoxyglucose F18 therapeutic use Hodgkin Disease diagnosis Lymphoma, Non-Hodgkin diagnosis Lymphomas Imaging Positron Emission Tomography Rademaker, Jürgen Sonstige oth Radiologic clinics of North America 46,2 (DE-604)BV000003369 46,2 HBZ Datenaustausch application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=016712650&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
| spellingShingle | Imaging of lymphoma Radiologic clinics of North America Diagnostic Imaging Fluorodeoxyglucose F18 therapeutic use Hodgkin Disease diagnosis Lymphoma, Non-Hodgkin diagnosis Lymphomas Imaging Positron Emission Tomography |
| title | Imaging of lymphoma |
| title_auth | Imaging of lymphoma |
| title_exact_search | Imaging of lymphoma |
| title_exact_search_txtP | Imaging of lymphoma |
| title_full | Imaging of lymphoma guest ed. Jürgen Rademaker |
| title_fullStr | Imaging of lymphoma guest ed. Jürgen Rademaker |
| title_full_unstemmed | Imaging of lymphoma guest ed. Jürgen Rademaker |
| title_short | Imaging of lymphoma |
| title_sort | imaging of lymphoma |
| topic | Diagnostic Imaging Fluorodeoxyglucose F18 therapeutic use Hodgkin Disease diagnosis Lymphoma, Non-Hodgkin diagnosis Lymphomas Imaging Positron Emission Tomography |
| topic_facet | Diagnostic Imaging Fluorodeoxyglucose F18 therapeutic use Hodgkin Disease diagnosis Lymphoma, Non-Hodgkin diagnosis Lymphomas Imaging Positron Emission Tomography |
| url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=016712650&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| volume_link | (DE-604)BV000003369 |
| work_keys_str_mv | AT rademakerjurgen imagingoflymphoma |